Abstract | Several conventional methods of bariatric surgery can induce long-term remission of type 2 diabetes mellitus (T2DM); novel gastrointestinal surgical procedures are reported to have similar effects. These procedures also dramatically improve other metabolic conditions, including hyperlipidemia and hypertension, in both obese and nonobese patients. Several studies have provided evidence that these metabolic effects are not simply the results of drastic weight loss and decreased caloric intake but might be attributable, in part, to endocrine changes resulting from surgical manipulation of the gastrointestinal tract. In this Review, we provide an overview of the clinical evidence that demonstrates the effects of such interventions-termed metabolic surgery-on T2DM and discuss the implications for future research. In light of the evidence presented here, we speculate that the gastrointestinal tract might have a role in the pathophysiology of T2DM and obesity.
Introduction
Several conventional methods of bariatric surgery induce long-term remission of type 2 diabetes mellitus (T2DM) and dramatically improve other metabolic abnormalities, such as hyperlipidemia and hypertension. [1] [2] [3] [4] Previous studies demonstrated that these metabolic effects are not only attributable to drastic weight loss and diminished caloric intake, 1, 5, 6 but also to endocrine changes that result from surgical manipulation of the gastro intestinal tract. Here, we evaluate the clinical evidence for the effects of metabolic surgery on T2DM and discuss the implications for future research.
Bariatric and metabolic surgery
Surgical techniques Bariatric surgical procedures have traditionally been divided into three categories: restrictive, malabsorptive or mixed surgery. This classification is based on the assumption that bariatric surgery controls only food intake and/or nutrient absorption. According to this conventional view, restrictive surgical procedures, such as laparoscopic adjustable gastric banding (LAGB) or vertical banded gastroplasty (VBG), induce early satiety during meals by decreasing the volume of the stomach (Figure 1a ,b). Malabsorptive procedures (Figure 1c,d ), such as bilio-pancreatic diversion (BPD), divert bile into the terminal segment of the ileum so that bile and food are only mixed in the final 50-100 cm of the small bowel, thereby drastically reducing nutrient absorption. Mixed procedures, such as Roux-en-Y gastric bypass (RYGB), involve restriction of the stomach and bypass of the small bowel, which is, however, shortened much less so than it is in BPD (Figure 1c ). Other novel procedures, such as duodenal-jejunal bypass (DJB), ileal interposition and sleeve gastrec tomy are becoming increasingly popular owing to their ability to cause dramatic weight loss and/or substantial improvement of glycemic regulation among both obese and nonobese patients ( Figure 2) . Nevertheless, RYGB, LGB and BPD remain the most widely used treatments for morbid obesity. 1 
Outcomes of conventional bariatric procedures
Traditional methods of bariatric surgery are associated with high rates of remission of T2DM, as demonstrated by a meta-analysis of 136 studies that included a total of 22,094 patients who underwent bariatric surgery as a treatment for morbid obesity. 1 Although most of the studies were retrospective and lacked long-term followup (duration of follow-up was 1-3 years), the results were still impressive: the mean ratios of patients with resolution of T2DM after LAGB, VBG, RYGB and BPD were 48%, 68%, 84%, and 98%, respectively ( Table 1) .
The multicenter, prospective, controlled Swedish Obese Subjects (SOS) study 7 compared the effects of bariatric surgery (LAGB: n = 156; VBG: n = 451; RYGB: n = 34) with those of nonsurgical weight-loss treatment (control group) in matched patients with obesity. Bariatric surgery resulted in a 16.1% mean weight loss at 10 years after surgery (RYGB: 25.0 kg; LAGB: 13.2 kg; VBG: 16.5 kg), compared with a small weight gain observed in the control group. Fasting glycemia tended to increase during the study in the control group (18.7% at 10 years), whereas a substantial decrease in fasting glycemia was detected in surgically treated patients at 2 years (13.6%) and 10 years (2.5% overall decrease, ranging from 0.8% for gastric banding and 10% for gastric bypass). Furthermore, at 10 years, the relative risk of incident T2DM was three times lower, and the rates of recovery from T2DM were three times greater, for patients who underwent surgery than for individuals in the control group.
Some studies evaluated the procedure-specific effects on T2DM, including a randomized, controlled trial in which 60 patients with BMi values of 30-40 kg/m 2 received either standard therapy (medical and/or behavioral) or LAGB plus standard therapy. 8 2 years after surgery, remission of T2DM (defined as having a fasting glucose level below 7 mmol/l and HbA 1c <6.2% without the use of pharmaco therapy) was seen in 73% of patients who underwent surgery and standard therapy versus 13% of patients who received standard therapy alone. Two large case-series studies that included patients with T2DM or impaired glucose tolerance documented normalization of HbA 1C levels after RYGB without antidiabetic medication in 89% and 82% of patients, respectively.
9,10 A retro spective study on the effect of BPD in 243 patients with T2DM showed normalization of glycemia in 97% of patients at 10 years after surgery.
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Sleeve gastrectomy has also been shown to dramatically improve symptoms of T2DM, at least in the short term, as reported in a 12-month, prospective study in which 84.6% of patients achieved complete remission of T2DM. 12 However, a gradient of efficacy seems to exist among the various surgical procedures in the rates of normalization of glycemia achieved without pharmacological intervention, as suggested by a study of 72 patients with T2DM who underwent one of three bariatric surgeries over a 30-month period in a single institution. 13 After a mean duration follow-up of 13 months, 17% of the patients who underwent LAGB experienced diabetes remission, whereas remission occurred in 33% and 69% of patients who underwent sleeve gastrectomy or RYGB, respectively. improvement of T2DM after gastrointestinal surgery has also been reported in patients with relatively mild forms of obesity and in nonobese individuals. in a randomized, controlled trial, 80 patients with a BMi of 30-35 kg/m 2 were treated with either a strict medical regimen (that included a very low calorie diet, lifestyle modification and pharmacotherapy) or LAGB. 4 At baseline, 38% of patients in each group had been diagnosed with the metabolic syndrome; 2 years after surgery, the metabolic syndrome was prevalent in 24% of nonsurgically treated patients but in only 3% of those treated with surgery. Another research group reported remarkable reduction of fasting plasma glucose levels in a prospective series of 37 patients with BMi <35 kg/m 2 who underwent laparoscopic RYGB. 14 Remission of T2DM after BPD in patients with nonmorbid obesity was reported in two other studies. 15, 16 Outcomes of novel procedures Cohen and colleagues 17 reported the first two patients who underwent duodenal-jejunal bypass (DJB) for T2DM; these patients had BMis of 29 kg/m 2 and 30 kg/m 2 , respectively. After surgery, the patients' HbA 1C levels normalized within 3 months, and stabilized after 9 months at 5-6% (from 8-9% preoperatively). importantly, neither patient lost weight, which suggests that surgery evoked weight-independent antidiabetic mechanisms. in another study, marked reductions were observed in fasting glycemic levels and HbA 1C levels after laparoscopic DJB, and 18 out of 20 patients with BMi <30 kg/m 2 discontinued antidiabetic medications. 18 Another study found a decrease in antidiabetic medication requirements after DJB but only modest improvements of HbA 1C levels (from 9.4% to 8.5%) and blood glucose levels (from 11.60 mmol/l to 8.55 mmol/l). 19 ileal interposition alone or in combination with sleeve gastrectomy among 60 patients with T2DM and BMi 24-34 kg/m 2 resulted in adequate glycemic control in 87% of patients at a mean follow-up of 7.4 months. 20, 21 endoluminal duodenal-jejunal sleeve is a flexi ble plastic sleeve that excludes the proximal intestine from alimentary flow, analogous to the surgical bypass in a standard RYGB or DJB. The device can be implanted endoscopically without disrupting bowel continuity or creating surgical anastomoses and has been reported to improve glucose homeostasis in both animal and human studies. 22, 23 nonglycemic metabolic effects of surgery in addition to substantially improving hyper glycemia, bariatric or metabolic surgery might ameliorate several other symptoms, including hyperlipidemia and hyper tension. Results of a meta-analysis 1 showed marked decreases in levels of total cholesterol, LDLcholesterol and tri glycerides after bariatric procedures. Approximately 70% of patients experienced an improvement in hyperlipidemia, whereas 79% of patients experi enced improvement or resolution of hyper tension. 1 Surgical improvement of hyperlipidemia and hyper tension has also been reported in patients with BMi <35 kg/m 2 . 2, 3, 16 These findings indicate that bari atric or metabolic surgery offers health benefits other than just weight loss and glycemic control. Several clinical investigations have demonstrated that bari atric operations improve long-term survival in patients with severe obesity, both with and without T2DM, when compared with matched control individual who do not undergo surgery: bariatric surgery is associated with decreases in mortality ranging from 33% to 89%. [24] [25] [26] [27] [28] [29] in a large case-control study, 7,925 patients underwent RYGB whereas 7,925 matched controls did not undergo surgery of any kind. After a mean follow-up of 8.4 years, surgery reduced overall mortality by 40%, cardiovascular mortali ty by 56%, cancer mor tality by 60% and diabetesrelated mortality by 92%. 30 in the SOS study, patients in the surgical group experienced a 24% nonadjusted decrease in overall mortality compared with matched controls; the most prominent decreases were observed in cancer-related and cardiovascular mortality (38.0% and 20.5%, respectively). 31 
Safety of bariatric and metabolic surgery
The frequent misconception that bariatric surgery is associated with markedly elevated rates of complications and mortality is not supported by the available data. A meta-analysis of 361 studies that included a total of 85,048 patients showed an overall mortality of 0.28% within 30 days after surgery, and a mortality of 0.35% between 30 days and 2 years after surgery. 32 Several other studies reported surgical mortality of 0.25-0.50%. [33] [34] [35] [36] The Longitudinal Assessment of Bariatric Surgery consortium conducted a multicenter, prospective observational study of 30-day outcomes in patients who underwent bariatric surgery at 10 clinical sites in the uS between 2005 and 2007. 37 The 30-day death rate among patients who underwent RYGB or LAGB was 0.3%, and in total 4.1% of patients experienced at least one major adverse event. 37 Of note, mortality rates associated with bariatric surgery are equivalent with those of several common abdominal surgeries, such as laparoscopic cholecystectomy, which has a mortality rate of 0.3-0.6% in the uS. 38 Another study, which analyzed the data of more than 9,500 patients who underwent bariatric surgery at 652 hospitals in the uS, showed an impressive 21% decline in 6-month, risk-adjusted complication rates over the past decade. 39 The study also found that inpatient complication rates fell from 24% to 15%, despite inclusion of a high percentage of elderly and ailing operative patients. These data demonstrate that over the past several years, morbidity and mortality associated with bariatric surgery have steadily declined. Such improvements have been largely attributed to the widespread use of minimally invasive laparoscopic techniques, in addition to other factors, 40, 41 such as implementation of centers of excellence and greater experience with the procedures. during this procedure, a surgical stapler is used to create a small, vertical gastric pouch. The upper pouch, which is completely separated from the gastric remnant, is anastomosed to the jejunum, whereas the excluded biliary limb is anastomosed to the alimentary limb. After surgery, ingested food bypasses about 95% of the stomach, the entire duodenum and a portion of the jejunum; however, bile and nutrients mix in the distal jejunum and can be absorbed through the remaining portion of the small bowel. Biliopancreatic diversion involves a horizontal c | or a vertical resection of the stomach (d | also known as 'sleeve gastrectomy' or, in the latter case, a 'duodenal switch'). The reduced stomach is anastomosed to the distal 250 cm of the small intestine. The excluded small intestine, which carries the bile and pancreatic secretions, is connected to the alimentary limb. Bile and nutrients mix in a short segment of small bowel, the only site where lipids and starches are absorbed; noncaloric nutrients are absorbed in the alimentary limb.
NATuRe ReViewS | EndOCRinOLOGy Control of T2DM by metabolic surgery
Effects on glucose and insulin homeostasis Several studies suggest that RYGB and BPD might improve T2DM by enhancing insulin sensitivity 42 and/or by improving β-cell function. The beneficial effect of gastric bypass surgery on β-cell function is supported by two observations. One is represented by the increasing rate of reported hyperinsulinemic hypoglycemia in patients who have undergone RYGB, 43 which suggests that the postoperative milieu after RYGB can stimulate the function and possibly the growth of β cells and that this stimulus, in some cases, might go too far. Further support derives from the observation that gastric bypass surgery can also restore acute β-cell response to glucose, which suggests that the defect in glucoseinduced insulin secretion, which is typical of T2DM, is a reversible abnormality. 44 Gastric bypass surgery also consistently improves oral glucose tolerance, both in animals and humans. A study where oral glucose tolerance tests were performed in nine obese women with T2DM before and 1 month after RYGB and in 10 matched women after a diet-induced, equivalent weight loss (10 kg) showed a dramatic improvement of oral glucose tolerance and an increase in the levels of glucagon-like peptide-1 (GLP-1) and in the overall incretin-related effect (glucose-dependent increase in insulin secretion) after RYGB, but not in the control group. 45 weight-independent antidiabetic effects increasing evidence suggests that certain types of surgical manipulations of the gastrointestinal tract ameliorate T2DM by mechanisms other than weight loss and diminish ed caloric intake. A direct role of surgical manipulation of the gastrointestinal tract on diabetes mellitus was suggested by an experiment in nonobese diabetic rats (Goto-Kakizaki strain) that underwent DJB surgery. 46 These rats experienced substantially greater improvement of glucose homeostasis than matched control rats that had undergone sham operation, diet restriction or therapy with insulin-sensitizing drugs. 46 Similar findings have been reported in other studies that used the same animal model [47] [48] [49] as well as in other rodent models of diet-induced insulin resistance. 50, 51 Numerous cases of glycemic improvement have been reported in humans following experimental gastrointestinal procedures that cause little to no weight loss. 17, 18 Additional evidence of weight-independent mechanisms of T2DM control derives from observations that bypass surgical procedures induce higher rates of T2DM remission than restrictive forms of bariatric surgery or nonsurgical interventions, despite equivalent weight loss, consistent with the study discussed above that compared the results of RYGB and dieting. 45 in a randomized, controlled trial that compared sleeve gastrectomy and gastric bypass, greater rates of T2DM remission were found among patients treated with gastric bypass than among those treated with sleeve gastrectomy, despite equivalent weight loss in both groups. Similar results were found in studies that compared LAGB and . Some variants of this procedure preserve the pylorus. This procedure might also be associated with a sleeve resection of the stomach to reduce the risk of marginal ulcerations and gastroparesis, as well as to increase weight loss if performed in patients with obesity. b | Long-term data about the efficacy of this procedure and its variants are not yet available. c | Sleeve gastrectomy not only reduces the capacity of the stomach but also eliminates the ghrelin-rich gastric fundus, which might contribute to the beneficial effects of the procedure. Sleeve gastrectomy has been also shown to improve type 2 diabetes mellitus in patients with severe obesity. The efficacy of the procedure in the long-term needs to be further investigated. d | Ileal interposition: during this procedure, a small segment of ileum (with its intact vascular and nervous supplies) is surgically interposed into the proximal small intestine, which increases its exposure to ingested nutrients. Ileal interposition can be performed alone or in association with sleeve gastrectomy and duodenal exclusion. The procedure requires three anastomoses (gastric bypass operations include two). The long-term effects of this procedure are unknown. RYGB. 52, 53 These observations suggest that manipulation of gastrointestinal anatomy with bypass surgery directly influences metabolic pathways, which ultimately results in improved glucose homeostasis and body-weight regulation. As a consequence, weight loss and T2DM control might be considered two separate outcomes of gastrointestinal surgery, which means that improvement of glycemia is not necessarily secondary to weight loss.
Possible neuroendocrine mechanisms
Gastrointestinal bypass procedures connect two otherwise separated segments of the gastrointestinal tract, thereby allowing nutrients to reach the distal portion of the small intestine more rapidly than usual and preventing the contact of nutrients with much of the stomach, the entire duodenum and part of the jejunum. Two major hypotheses exist for improvement of glycemia following gastrointestinal surgery. According to the 'lower intestinal hypo thesis' 54 (also known as 'distal' or 'hindgut' hypo thesis 55 ), the rapid delivery of nutrients to the lower intestine increases stimulation of L cells, which results in increased secretion of hormones that enhance insulin release and/or insulin action (for example, GLP-1). This would decrease blood glucose levels. According to the 'upper intestinal hypothesis' 54 (also defined as 'proximal' of 'foregut' hypothesis 55 ), gastro intestinal bypass reduces the secretion of gastrointestinal factors that decrease insulin secretion and/or promote insulin resistance. Reduction of the amount of these putative anti-insulin factors (or anti-incretins) would increase insulin action and/or secretion, thereby improving symptoms of T2DM. Although the proximal and distal hypotheses are often conceptualized in terms of the release of hormones, they are also compatible with the theory that altered nutrient flow triggers neural signal ing rather than hormone release.
The distal and proximal hypotheses are often presented as mutually exclusive. Although such presentation might be convenient for didactic purposes, no reported data precludes the possibility that the distal and proximal mechanisms both contribute to the efficacy of gastric bypass procedures. For example, the exclusion of the proximal bowel per se might cause changes in levels of distal gut hormones as proximal signals are involved in the regulation of L-cell secretory functions. 56 A number of gastrointestinal hormonal changes have been reported to occur following gastric surgery, consistent with the hypotheses that alterations in gastrointestinal anatomy affect endocrine functioning of the gut. For example, RYGB induces substantial hormonal changes, even before weight loss takes places. 57 increased levels of peptide YY and GLP-1 45, [58] [59] [60] [61] have been consistently reported in several animal and human studies. RYGB also seems to alter secretion of ghrelin 62 and gastric inhibitory polypeptide. 57, 63 These hormones are all involved in the regulation of energy homeostasis via their effects on peripheral organs, as well as the brain. Although the exact molecular mechanisms that underlie the improvements in metabolism following gastric bypass surgery are not known, these findings establish that changes in gastrointestinal anatomy have profound effects on the gastrointestinal tract's control of metabolism. Furthermore, as a number of gastrointestinal hormones and neural signals are produced at various sites of the gastrointestinal tract, different surgical methods might activate distinct mechanisms of action.
Rationale for a paradigm shift
From bariatric to metabolic surgery The evidence provided here supports the need for a conceptual shift in the way gastrointestinal surgery should be regarded. Currently, the term 'bariatric' (which originates from the Greek word for 'weight' [baros]) reflects the perceived notion that gastrointestinal surgery is used primarily to induce weight loss. However, strong evidence shows that bariatric surgery not only induces dramatic weight loss but also improves symptoms of T2DM, hypertension and hyperlipidemia, and, as noted above, the metabolic improvements are associated with endocrine effects and can even precede substantial weight loss. On the basis of this evidence, the term 'metabolic' surgery seems more appropriate as it refers to the effects of gastrointestinal surgery on the metabolic syndrome as a whole, while also capturing the metabolic nature of its mechanisms of action.
need for revision of BMi-based criteria A patient's BMi is used as the primary eligibility criterion for surgical treatment of severe obesity. According to the NiH guidelines, 64 only patients with a BMi >40 kg/m 2 or with a BMi >3 kg/m 2 accompanied by comorbidities, such as T2DM, are eligible for gastrointestinal surgery. Although this approach is convenient, BMi does not accurately predict the diabetes-related risk of mor bidity and mortality. Moreover, no evidence suggests that specific BMi cut-off values can serve as predictors of success ful metabolic control after gastrointestinal surgery. As described above, several studies have successfully demonstrated that gastrointestinal surgery can be a life-saving procedure for individuals with severe obesity. Such surgery also seems to dramatically improve hyperlipidemia, hypertension and hyperglycemia in nonobese individuals, thereby providing a plausible therapeutic alternative to reducing cardiovascular risk in selected patients. Therefore, we consider it inappropriate that BMi continues to be used by clinicians and insurance companies as the sole criterion to determine patients' eligibility for surgical treatment of T2DM and the metabolic syndrome.
A role for intestinal factors in T2dM?
The gastrointestinal tract is not commonly con sidered in discussions of the etiology of insulin resistance and T2DM. Attention is usually focused on the liver, muscle, adipose tissue and the pancreatic β cells, which are the major peripheral organs and tissues involved in the control of whole-body energy homeostasis. in the follow ing discussion, we provide a number of reasons why the gastrointestinal tract should be included in these considerations.
The gastrointestinal tract is the first organ to come into contact with the nutrient load of a meal and, as an endocrine organ, it transmits this information via hormonal secretion and direct neural signaling to peripheral tissues, as well as the brain, thereby modulating the control of metabolism. As a consequence, the gastro intestinal tract has a major role in the integration of nutrients with metabolic responses and changes in its anatomy can, predictably, have profound effects in the control of metabolism. in fact, the effects of surgical manipulation of the intestine on T2DM, independent of weight-loss, are consistent with the hypothesis that the gastrointestinal tract has a physio logical role in glucose homeostasis. Owing to the importance of its physiological role and the number of regulatory signals that are produced in response to nutrient intake, it is also plausible that the gastrointestinal tract might also have a role in abnormalities of glucose homeostasis, such as insulin resistance and T2DM.
Dysfunction of the gastrointestinal tract could provide a potential explanation for the link between excess nutrition and the development of insulin resistance and T2DM. The passage of excess nutrients in general or an increase in the passage of specific nutrients through the gastrointestinal tract could trigger intestinal neuro endocrine dysfunction, possibly owing to an over stimulation of neuroendocrine functions (see the discussion below on anti-incretin theory). Consistent with the hypothesis of a dysfunctional intestinal response to nutrient stimulation, all forms of restriction of nutrient passage throughout the intestine invariably result in improvement of T2DM, and the data suggest a positive correlation between the decrease of nutrient stimulation ('intestinal rest') and the degree of improvement of T2DM (that is, diet, restrictive surgery and gastric bypass surgery are associated with relatively small, medium and relatively great improvement, respectively) ( Figure 3) . The epidemic growth of the incidence of T2DM also suggests that environmental or infectious agents could contribute to the development of this disease. Although considering the rising incidences of obesity and T2DM from the perspec tive of an infectious epidemic is highly speculative, this approach is supported by some studies. 65 indeed, the gastro intestinal tract is the organ that is first exposed to food-borne toxins or infectious agents, and as it is involved in the control of metabolism, such insults could have profound metabolic effects. Notably, the microbiota of the gut can affect the control of energy metabolism, and, therefore, changes in the microbiota might contribute to the epidemic of obesity and T2DM. 66 Future studies are required to unravel the potential role and contributions of infectious agents, environmental toxins and changes in the gut microbiota on the rise of these abnormalities.
The anti-incretin hypothesis As discussed above, a variety of arguments suggest that the gastrointestinal tract is involved in the development of T2DM and is a potential target for the treatment of this disease. Nevertheless, we still do not understand the role of the gastrointestinal tract at a mechanistic level.
Although a number of possible mechanisms are known, here we discuss only the 'anti-incretin' hypothesis, which could explain both the effects of gastrointestinal surgery on T2DM and the role of the gastrointestinal tract in the physiology and pathophysiology of glucose homeostasis. incretins include gut hormones, such as GLP-1 and gastrointestinal peptide, whose secretion is triggered by the passage of nutrients through the small bowel. These hormones increase glucose-stimulated insulin secretion by pancreatic β cells and also affect gastric emptying, nitrite influx and β-cell proliferation (via anti-apoptotic effects). 67 The 'anti-incretin' theory posits the existence of nutritionally-stimulated, gastrointestinal, neuroendocrine signals that antagonize the effects of incretins. 68 A normal, physiologic balance between incretins and 'anti-incretins' would ensure normal excursions of blood glucose and proper β-cell function. The anti-incretin theory suggests that an increase or untimely production of the anti-incretin signal could disrupt the incretin-antiincretin homeostatic mechanism and ultimately affect the functions of a number of organs that are involved in the regulation of metabolism (such as β cells, adipose tissue and the brain). This theory predicts that in patients with T2DM, gastrointestinal bypass surgery might prevent the release of excess anti-incretins, which restores the proper incretin-anti-incretin balance, and eventually results in the improvement of T2DM. A corollary of this According to this hypothesis, overstimulation of the GI tract (by overeating and/or the presence of chemical or biological stimuli in modern diets) could lead to insulin resistance, obesity and T2DM, whereas all forms of restriction of nutrients' transit could improve these conditions. Indeed, diet might improve T2DM not just because of a restriction of caloric intake, but possibly owing to the reduced stimulation of abnormal intestinal mechanisms. Likewise, restrictive surgery could improve T2DM by reducing the nutrient load even further. Bypass operations, which completely and indefinitely inactivate a large part of the intestine, reduce nutrient-related stimuli more than any other approach and are the most effective ways of improving T2DM, obesity and insulin resistance syndrome. Abbreviations: GI, gastrointestinal; T2DM, type 2 diabetes mellitus. hypothesis is that in some patients gastrointestinal bypass surgery results in an underproduction of 'anti-incretins' , which might cause a shift toward an exaggerated incretin effect, thereby increasing the risk of postprandial hyperinsulinemia and hypoglycemia. we must emphasize, however, that this hypothesis has not been confirmed and putative anti-incretins produced by the gastrointestinal tract have not been identified to date.
An alternative hypothesis regarding the effect of bariatric surgery on insulin sensitivity is that exclusion of portions of the gut reduces the flux of nutrients, and this reduced flux is directly responsible for the beneficial effects associated with surgery. Severe caloric restriction acutely improves insulin resistance, although the underlying mechanism for this effect is not known. This effect could be directly related to the change in the flux of nutrients (that is, independent of any effects on the secretion of known and hypothesized gut hormones). Alternatively, the change in nutrient flux could affect the balance of gut hormones (including hypothetical antiincretins) and the change in hormone milieu might be responsible for changes in insulin sensitivity. Regardless of the explanation for the effects of altering nutrient flux through the gut, a better understanding of the role of the gut in the control of insulin sensitivity will certainly support the future development of treatments for insulin resistance and T2DM.
Conclusions
Considering the escalating pandemic of T2DM, clinicians must recognize the need for improved therapeutic options. when behavioral and pharmacological interventions fail to manage T2DM, metabolic surgery offers an effective alternative, with the potential of complete remission of the disease. As the data presented in this article indicate, traditional bariatric or metabolic surgeries are highly safe and effective in patients with severe obesity and T2DM. Furthermore, gastro intestinal bypass techniques improve glucose homeo stasis through mecha nisms beyond reduced caloric intake and weight loss. Continued research to better understand the weight-independent antidiabetic mechanisms of gastrointestinal surgery and the role of the gastrointestinal tract in the physiology and pathophysiology of glucose homeo stasis might facilitate the design of less invasive interventions, lead to important discoveries, and help identify targets for novel drug development, ultimately serving to improve the treatment of obesity and T2DM.
Review criteria
Articles were primarily identified from a PubMed search; search terms included "bariatric surgery", "type 2 diabetes", "RY gastric bypass", "biliopancreatic diversion", "gastric banding", "diabetes surgery", "gut hormones", and "GLP-1". We also manually searched articles through the reference lists of selected papers for further leads. Although the years of publication for the selected articles ranged from 1991 to 2009, the majority of the articles were published in the past 5 years, as the field of metabolic surgery and the belief that such surgery can directly influence diabetes control is still relatively novel.
